Department of General Surgery, The People's Hospital of XiaJin Affiliated to Shandong First Medical University, XiaJin, China.
Department of Emergency Surgery, The Second People's Hospital of Liaocheng, Linqing, China.
Clin Res Hepatol Gastroenterol. 2022 Aug-Sep;46(7):101913. doi: 10.1016/j.clinre.2022.101913. Epub 2022 Mar 26.
Chaperonin-containing tailless complex polypeptide 1 subunit 6A (CCT6A) promotes several gastrointestinal-cancer malignant behaviors, while its clinical value in surgical gastric cancer is not clear. Hence, we aimed to investigate this issue.
Totally, tumor and adjacent specimens from 262 surgical gastric cancer patients were collected for measuring CCT6A protein level by immunohistochemistry (IHC) staining; meanwhile, specimens from 109 patients were used for evaluating CCT6A mRNA expression by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
CCT6A IHC score and CCT6A mRNA expression were upregulated in the tumor tissue compared with the adjacent tissue (both P<0.001). Besides, elevated CCT6A IHC score was correlated with larger tumor size (P<0.001), advanced T stage (P=0.001), N stage (P=0.003) and tumor node metastasis (TNM) stage (P=0.001). Meanwhile, increased CCT6A mRNA expression was associated with higher T stage (P=0.008) and TNM stage (P=0.020). Besides, CCT6A protein high (P=0.017) and CCT6A mRNA high (P=0.047) were correlated with unfavorable disease-free survival (DFS), whereas neither CCT6A protein nor CCT6A mRNA expression was related to the overall survival (OS) (both P>0.05). Additionally, the multivariable Cox's proportional hazards regression analysis revealed that CCT6A protein high was independently correlated with shorter DFS (adjusted hazard ratio (HR): 2.032, P=0.005), but not with OS.
CCT6A is upregulated with its overexpression linking with advanced T stage, TNM stage and unfavorable DFS in surgical gastric cancer patients.
伴侣蛋白 1 无尾复合物多肽 6A（CCT6A）可促进多种胃肠道癌恶性行为，但其在外科胃癌中的临床价值尚不清楚。因此，我们旨在探讨这一问题。
共收集 262 例外科胃癌患者的肿瘤及相邻标本，采用免疫组织化学（IHC）染色法检测 CCT6A 蛋白水平；同时，采用逆转录定量聚合酶链反应（RT-qPCR）检测 109 例患者的 CCT6A mRNA 表达。
肿瘤组织中 CCT6A IHC 评分和 CCT6A mRNA 表达均高于相邻组织（均 P<0.001）。此外，CCT6A IHC 评分升高与肿瘤较大（P<0.001）、T 期较晚（P=0.001）、N 期（P=0.003）和肿瘤淋巴结转移（TNM）分期较晚（P=0.001）相关。同时，CCT6A mRNA 表达升高与 T 期较高（P=0.008）和 TNM 分期较高（P=0.020）相关。此外，CCT6A 蛋白高（P=0.017）和 CCT6A mRNA 高（P=0.047）与无病生存（DFS）不良相关，而 CCT6A 蛋白和 CCT6A mRNA 表达均与总生存（OS）无关（均 P>0.05）。此外，多变量 Cox 比例风险回归分析显示，CCT6A 蛋白高与较短的 DFS 相关（调整后的风险比（HR）：2.032，P=0.005），但与 OS 无关。
CCT6A 在外科胃癌患者中上调，其过表达与 T 期较晚、TNM 分期和 DFS 不良相关。
